Haleon PLC Sponsored ADR (NYSE:HLN) Receives $12.33 Consensus Price Target from Brokerages

Haleon PLC Sponsored ADR (NYSE:HLN) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $12.3250.

A number of research firms recently commented on HLN. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research note on Monday, December 15th. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft lowered Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Finally, HSBC raised Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st.

Institutional Trading of Haleon

A number of hedge funds and other institutional investors have recently made changes to their positions in HLN. Private Trust Co. NA grew its position in Haleon by 13.3% in the second quarter. Private Trust Co. NA now owns 8,794 shares of the company’s stock worth $91,000 after buying an additional 1,032 shares during the last quarter. IHT Wealth Management LLC boosted its stake in shares of Haleon by 6.9% during the 4th quarter. IHT Wealth Management LLC now owns 16,205 shares of the company’s stock worth $164,000 after acquiring an additional 1,049 shares in the last quarter. National Bank of Canada FI boosted its stake in shares of Haleon by 6.7% during the 3rd quarter. National Bank of Canada FI now owns 17,385 shares of the company’s stock worth $156,000 after acquiring an additional 1,099 shares in the last quarter. Oppenheimer & Co. Inc. grew its holdings in shares of Haleon by 4.7% in the 4th quarter. Oppenheimer & Co. Inc. now owns 24,744 shares of the company’s stock worth $250,000 after acquiring an additional 1,100 shares during the last quarter. Finally, Cary Street Partners Financial LLC raised its position in shares of Haleon by 20.1% during the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock worth $69,000 after purchasing an additional 1,113 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Haleon Stock Performance

Shares of HLN opened at $11.26 on Friday. The firm has a market capitalization of $50.12 billion, a PE ratio of 28.86 and a beta of 0.19. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average price of $10.35 and a 200 day moving average price of $9.77. Haleon has a 52-week low of $8.71 and a 52-week high of $11.42.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.